HUS-YHTYMA

Their core work

HUS (Helsinki University Hospital) is Finland's largest hospital district, serving as a major clinical research center that bridges hospital-based patient care with translational research. They contribute real-world clinical data, patient cohorts, and clinical trial infrastructure to European research consortia focused on neurological disorders, cancer, pain management, and pediatric medicine. Their strength lies in embedding research directly into hospital workflows — from AI-driven care pathway optimization to large-scale clinical validation of biomarkers and digital health tools.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), HUS focused on classical clinical research — disease-specific biomarker discovery, neuroprotection studies (stroke, Parkinson's), pain characterization, and off-patent drug repurposing. From 2020 onward, a clear digital transformation is visible: artificial intelligence, machine learning, digital pathology, and genomic prediction became dominant themes across their portfolio. This shift reflects a hospital system moving from being a clinical data provider to actively driving AI-powered clinical decision support and precision medicine.

HUS is rapidly building capacity in hospital-embedded AI and genomic prediction, making them an increasingly valuable partner for projects that need clinical AI validation in a real hospital environment.

How they like to work

HUS operates predominantly as an active partner (14 of 18 projects), contributing clinical sites, patient data, and medical expertise rather than leading consortium management. They have coordinated twice — BOUNCE (breast cancer adaptation) and AICCELERATE (AI hospital pathways) — both in areas where clinical workflow ownership was essential. With 295 unique partners across 27 countries, they function as a well-connected clinical node that diverse consortia seek out for real-world validation.

HUS has collaborated with 295 distinct partners across 27 countries, reflecting broad European reach typical of a major university hospital. Their network spans academic medical centers, AI technology developers, pharmaceutical companies (via IMI), and pediatric research networks.

What sets them apart

HUS combines the scale of Finland's largest hospital district with direct access to Finnish national health registries and biobanks (e.g., FinnGen), making them uniquely positioned for population-level clinical validation. Unlike pure research institutes, they can deploy and test AI tools, biomarkers, and treatment protocols in live hospital workflows serving over 2 million patients. For consortium builders, this means a partner who can move findings from bench to bedside within a single organization.

Highlights from their portfolio

• c4c
  Largest single grant (EUR 2.3M) — a flagship European network building clinical trial infrastructure specifically for children and adolescents.
• AICCELERATE
  Coordinated by HUS (EUR 965K) — directly applies AI and machine learning to optimize hospital care pathways, reflecting their strategic shift toward digital health.
• AI-Mind
  Major investment (EUR 1.1M) in AI-based dementia screening using brain connectivity analysis — sits at the intersection of their neurology expertise and AI capabilities.